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SUMMARY 
 
It is vital to identify people with low recurrence risk of venous thromboembolism (VTE) so as 
to protect them from dangers of prolonged anticoagulation therapy. Among women who 
develop VTE following hormone use, the evidence as to whether their risk of recurrence is 
low if they cease this therapy is conflicting. We investigated whether women whose initial 
VTE event was hormone related have a lower risk of VTE recurrence than women whose 
initial event had no obvious cause (unprovoked). A cohort study which utilised the Clinical 
Practice Research Datalink linked to Hospital Episode Statistics data from England was 
conducted. We selected 4,170 women aged between 15 and 64 years who were diagnosed 
with a first VTE event between 1997 and 2011. Cox regression models were used to obtain 
hazard ratios (HR). Hormone users had 29% lower recurrence risk than non-users (adjusted 
HR=0.71; 95% CI 0.58-0.88), a relationship which existed both in women aged 15-44 years 
(predominantly OC users) and those aged 45-64 years (predominantly HRT users). In 
conclusion, having a hormone-associated VTE is associated with a lower recurrence risk 
than one which is unprovoked after discontinuation of the hormone containing 
preparation. Prolonged anticoagulation may therefore be unjustified in such women.  
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INTRODUCTION 
Globally, the incidence rate of venous thromboembolism (VTE) is estimated to be 1 to 2 per 
1000 person years, and it is the third most common cause of cardiovascular death after 
coronary heart disease and stroke (Anderson et al, 1991;  Silverstein et al, 1998;  Cushman 
M et al, 2004;  Tagalakis et al, 2013;  Raskob et al, 2014).  Besides, VTE has been reported to 
recur in about 30% of patients after a period of ten years (Prandoni P et al, 1996;  Heit et al, 
2001) and the recurrence risk is higher in patients whose index VTE is unprovoked or caused 
by a risk factor which is non-reversible (Hansson et al, 2000;  Prandoni et al, 2007;  Eischer 
et al, 2009;  Iorio et al, 2010). Recently, the incidence rate of VTE recurrence in the UK was 
estimated to be 4.9 per 100 person years (Martinez et al, 2014). Use of oestrogen has been 
linked to increased risk of VTE (Canonico et al, 2008;  Vinogradova et al, 2015) but it is 
unclear whether the risk of recurrence is reduced after cessation of oestrogen use. Existing 
evidence as to whether women whose index VTE is hormone related have lower recurrence 
than those whose index VTE is unprovoked is still inconclusive.  For instance, one large US 
population based study (Heit et al, 2000) comprising 1,244 participants reported a 42%  
lower VTE recurrence risk in users than non-users of OCs in an unadjusted analysis and a 
much earlier UK study (Badaracco and Vessey, 1974) also reported significantly lower 
proportion of VTE recurrences  in OC users than in non-users. This supports a finding from a 
secondary analysis of pooled data from seven separate cohorts which reported that 
women with a hormone-associated VTE had a 50% lower risk of VTE recurrence than those 
who’s initial VTE had no obvious cause (Douketis et al, 2011) and that hormone use at 
baseline was found to be an independent term in a subsequent risk calculator using the 
same studies (Tosetto et al, 2012). In contrast, several smaller studies which primarily 
addressed this hypothesis (Kyrle et al, 2004;  Christiansen et al, 2005;  Cushman et al, 2006;  
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Le Gal et al, 2010;  Le Moigne et al, 2013) reported no significant difference in the risk of 
VTE recurrence between women whose VTE was hormone related and women whose VTE 
was unprovoked.   
 
Current UK guidelines recommend that patients who develop a venous thromboembolic 
event receive either oral anticoagulants or low molecular weight heparin for 90 days, and a 
longer treatment duration is advised if the VTE is related to cancer or is unprovoked 
(National Institute of health and Clinical Excellence, 2012) . There is however considerable 
uncertainty as to the optimal duration of anticoagulation following a hormone-related VTE 
and as such they represent an important and sizeable group for whom VTE management 
decisions are uncertain (Baglin, 2012;  Palareti, 2012). Prolonged use of anticoagulants is 
risky in that it often results in bleeding in addition to the potential inconvenience of a daily 
heparin injection (Linkins et al, 2003;  Kyrle and Eichinger, 2005). Identifying populations 
with lower VTE recurrence is therefore pertinent in influencing treatment policies to protect 
patients from the dangers associated with prolonged anticoagulant whilst reducing VTE 
related healthcare costs which have been estimated at £640 million annually in the United 
Kingdom (National Institute of health and Clinical Excellence, 2012). 
 
Therefore, we analysed routinely collected data from a large cohort of women from 
England, to directly compare the VTE recurrence risk between women whose index VTE 
event was hormone related and women of the same age whose VTE event was considered 
to be unprovoked. As a secondary hypothesis we explored whether re-initiation of 
hormone use during the follow-up period increased the risk of VTE recurrence.  
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METHODS 
Data source 
 
The Clinical Practice Research Datalink (CPRD) database currently contains anonymised 
primary care data from 674 practices covering 11.3 million patients throughout the UK, of 
whom 4.4 million are currently alive and registered with a participating practice (Herrett 
et al, 2015). The CPRD is subjected to quality checks and a practice’s data is only used for 
time periods where it is of high enough quality for research (Williams et al, 2012). This is 
denoted by defining an up-to-standard (UTS) time period for each practice. The Hospital 
Episodes Statistics (HES) database consists of data on primary and secondary discharge 
diagnoses along with inpatient procedures for patients admitted to hospital (secondary 
care) from English CPRD practices linked to HES. All diagnoses are coded by use of 
International Classification of Diseases code system (ICD-10) (Health and Social Care 
Information Centre, 2014). Using the National Health Service number, post code, date of 
birth, and sex, CPRD practices were linked to HES (Eaton et al, 2008) and for this study 
period (1997 to 2011) 53% of the CPRD practices had linked data which was used to obtain 
the study cohort of women from England, providing an overall study population of 2.33 
million people. 
Study population 
This study comprised women between the ages of 15 years and 64 years who had a first 
ever index VTE event between 1997 and 2011. A VTE event was defined by a medical code 
for venous thromboembolism (ICD 10; I26, I80-I82) in either or both the CPRD and HES. 
Women were considered to have a valid index VTE if their recording of VTE was 
supplemented by anticoagulant prescriptions at any time within 90 days of the event. This 
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algorithm was validated in women of childbearing age with a positive predictive value of 
84% (Lawrenson et al, 2000). 
To minimise the possibility of an existing (prevalent) VTE event being counted as incident, 
women were excluded if they had a VTE event within 90 days of joining the practice or 
before their practice’s data were judged to be of research quality (up to standard). Also, 
those whose initial VTE event was related to surgery, pregnancy or malignancy were 
excluded as were those whose VTE event occurred within 2 weeks of an inpatient hospital 
admission lasting 3 days or more. This was necessary so as to only retain women whose VTE 
events were unprovoked (unknown cause) and those whose VTE events were hormone 
related.  
Participant initiation and follow up 
The study period commenced on the latest date of either the 15th birthday, when practice 
became up to standard or 90 days after registration with a participating CPRD practice. 
Follow up for purposes of our analysis began on the 30th day from the last anticoagulation 
prescription date following the index VTE event and ended on the earliest date of either VTE 
recurrence, death, resumption or initiation of hormonal use, transfer from a participating 
CPRD practice, 65th birthday or end of the study (2011 December 31st). Censoring upon 
resumption or initiation of hormonal use was deemed necessary as our focus was on 
whether a hormone-related VTE would be associated with a low risk of recurrence upon 
the assumption that this therapy would not be recommenced. 
Definition of hormone use (exposure) 
We defined women as hormone users if they had a prescription for oral contraceptives or 
hormone replacement therapy in the 6 months prior to the date of the index VTE. Both 
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‘progestogen only’ and combined OCs as listed under sections 7.3.1 and 7.3.2 of the British 
National Formulary were included together with all HRT combinations under 6.4.1.1. This 
group of women were referred to as users in this study. Our comparison group (termed 
non-users) was defined as women who had no record of OC/HRT use in the 6 months prior 
to their index VTE. We considered this to be a proxy for unprovoked VTE on the basis that 
women who’s VTE had an identified cause were excluded as described above. 
Definition of recurrent VTE event (outcome) 
Women were considered to have a recurrent VTE if they had a recording of VTE (either in 
primary or secondary care data) event at least 30 days after the last prescription for the 
index VTE. A recurrent VTE event was only considered to be valid if it was either 
accompanied by a new anticoagulant prescription within 90 days of the event or if a woman 
died within 30 days of the event. 
Statistical analysis 
All data management and analyses were performed using STATA version 14. Absolute rates 
of VTE recurrence per 1,000 person years and their 95% confidence intervals were 
computed by dividing the total number of VTE recurrences by the person years of follow up.  
Recurrence rates between hormone users and non-users were compared using Cox 
regression models and Hazard ratios were adjusted for age, calendar year (of index VTE), 
and duration of anticoagulation treatment. The Cox proportional hazard assumption was 
tested using Schoenfeld’s test. Analyses were then conducted in age strata of 15 to 44 years 
(predominantly OC users) and 45 to 64 years (predominantly HRT users). For all analyses we 
used a delayed entry model whereby the time unit in the Cox regression models was time 
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since date of the index VTE. This accounts for the differences in the underlying hazard 
between participants caused by variations in the duration of anticoagulation.   
Subgroup and sensitivity analyses 
First, given that anticoagulation treatment duration might have an impact on the risk of VTE 
recurrence and possibly influence the effect of other risk factors on VTE recurrence, we 
carried out a sub group analysis based on the duration of anticoagulation treatment 
following the index VTE (<90 days vs. 90 days or more) . Second, a sensitivity analysis was 
conducted by attuning the start of follow up from 30 days to 180 days following the last 
anticoagulation prescription, owing to concerns that a new VTE medical code early in the 
follow-up period may not relate to a new VTE event. Third, owing to the fact that the 
evidence for a thrombotic effect is weaker for progestogen only compounds than for 
combined OCs, we reclassified women who only took progestogen only preparations during 
the 6 months prior to the index date as unexposed. All analyses presented in the paper were 
rerun with the new exposure groupings and the results were very similar on all occasions 
(data not presented). 
Secondary analyses 
For our secondary research question of whether hormone initiation or resumption influenced the 
risk of VTE recurrence, Cox regression models were fitted in the same way as described above with 
two exceptions; 1) participants were no longer censored at the time of hormone 
initiation/resumption, and 2) hormone use was fitted as a time-varying covariate.  All patients 
were therefore unexposed at the commencement of follow-up and became exposed at the time of 
the first hormone prescription and were assumed to remain exposed for the remainder of the 
follow-up period. Analyses were stratified by the primary exposure, so for “users” exposure status 
changed at the time of resumption of hormonal therapy, whilst for “non-users” exposure status 
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changed at the time of a first prescription for OC/HRT. Women who did not initiate/resume 
hormone use were considered to be unexposed for the entire follow-up period. 
 
Ethical statement 
The study was approved by the CPRD’s Independent Scientific Advisory Committee (ISAC 
protocol No.13_211).  
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RESULTS 
Study population 
The initial study population comprised 6,598 women between the ages of 15 and 64 years 
who had a first VTE between 1997 and 2011. A total of 2,428 women were excluded 
because they also had record of pregnancy (531), surgery (85), previous cancer (1,564) 
and/or hospitalization (248) at the time of the index event. After exclusion of these 
potentially provoked VTE events, 4,170 women remained.  
 
The median age of the study population was 48 years (table I). In total, there were 1,196 
women (28.7%) whose index VTE was hormone related and 2,974 (71.3%) whose index VTE 
was unprovoked (non-users). Among women aged 15-44 years, 562 were users of OCs, of 
which 465 (82.6%) used combined OCs, and 40 were users of HRT at the time of their first 
VTE. Among women aged 45-64 years, 66 were users of OCs, of which 42 (63.6%) used 
combined OCs, and 522 were users of HRT.  
 
The median duration of anticoagulation therapy among all participants was 98 (IQR, 70-119) 
days with the majority of women (60.6%) had receiving anticoagulation therapy for 90 days 
or more. Users were more likely than non-users to receive anticoagulation for more than 90 
days (51% vs. 37%) among women aged 15-44 years. However, the trend was reversed for 
women aged 45-64 years, where non-users were more likely to receive anticoagulation for 
more than 90 days (63% v. 49%).  
 
After the end of anticoagulation, there was a total of 12,065 person-years of follow-up with 
a median follow-up time of 1.8 years (IQR 0.5 to 4.4 years), during which time 497(41.55%) 
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of the users resumed hormone use and 290 (9.75%) of the non-users commenced hormone 
use (and were therefore censored from further follow-up at this point). 
 
Recurrent VTE events  
Overall, 575 (13.8%) recurrent events were observed, of which 248 and 327 were in women 
aged 15 to 44 years and 45 to 64 years respectively. The percentage of women with 
recurrent VTE events was higher in non-users than in users (15.3% versus 9.5%). Recurrence 
percentages in those who had been prescribed anticoagulation for 90 or more days and 
those who were prescribed anticoagulation therapy for less than 90 days were 14.2% and 
13.5% respectively. 
 
Recurrence rates of VTE 
 
The overall VTE recurrence rate (table II) was 48 (95% CI 43.9-51.8) per 1,000 person years. 
Non-users had a higher rate of VTE recurrence (51 per 1,000 person-years; 95%CI 46.8-56.2) 
than users (37 per 1000 person-years; 95% CI 30.8-44.5). The risk of VTE recurrence (Fig. 1) 
was significantly lower in users than in non-users, with users being 28% less likely to have a 
VTE recurrence compared to non-users (adjusted HR 0.72, 95% CI 0.58-0.88). 
 
Age stratified VTE recurrence rates in users and non-users  
In women aged 15 to 44 years (table III), OC users were 29% less likely to have a VTE 
recurrence in comparison with non-users (HR 0.71, 95% CI 0.52-0.96).  Similarly, in women 
aged 45 to 64 years HRT users had 29% less likelihood of having a VTE recurrence than non-
users (HR 0.71, 95% CI 0.53-0.95).  
 
Sub group Analysis 
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Subgroup analysis according to anticoagulation therapy duration (table iii) showed that the 
VTE recurrence rates were not significantly different between users and non-users in 
women whose treatment lasted for less than 90 days. However, in those who had received 
anticoagulation therapy for 90 or more days, users were 33% less likely to have a VTE 
recurrence (95% CI 0.51-0.88) compared with non-users. A test for interaction between 
hormone therapy and duration of anticoagulation however was not statistically significant. 
 
Sensitivity Analysis 
In a sensitivity analysis (table IV), excluding person-time and VTE events in the first 180 days 
following the last anticoagulant prescription, the magnitude of the difference in recurrence 
rates between users and non-users was slightly stronger both overall and within the 
separate age groups.  
 
Secondary Analysis 
In this secondary analysis where women were no longer censored at the time of hormone 
initiation/resumption, there were a total of 634 VTE recurrences in 14,664 person-years of 
follow-up. Whilst overall rates of VTE recurrence were higher among women who did not 
resume hormone therapy, once the effect of delayed entry was taken into account in the 
Cox regression analysis no differences in VTE recurrence were observed (Table V). This 
was both the case in women classed as “users” in the primary analysis (exposure: 
resumption of OC/HRT use) and those classed as non-users (exposure: initiation of 
OC/HRT use). 
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DISCUSSION 
Summary of the main findings 
This was the largest study to investigate VTE recurrence risk in women aged 15 to 64 years 
using routinely collected healthcare data. We found that the VTE recurrence rate in English 
women aged 15 and 64 years was 48 per 1,000 person years similar to that found in a 
previous study (Martinez et al, 2014) on VTE recurrence using the CPRD.  
 
Overall, in women aged 15 to 64 years, a 29% lower VTE recurrence rate in users compared 
to non-users was observed, with similar risk reductions reported in the two age groups 
studied (15 to 44 years and 45 to 64 years). The study also found a significant reduction in 
hormone users among women whose initial anticoagulation treatment lasted for 90 or more 
days but not in those whose treatment lasted less than 90 days. Initiation or resumption of 
hormonal therapy during the follow-up period was not found to be associated with VTE 
recurrence.  
 
Strengths and Limitations 
Due to the size of this study the risk of a type II error was small. Furthermore, it was possible 
to stratify the study population so as to calculate VTE recurrence rates for both OC users 
and HRT users separately, and compare these risks with their respective comparison groups.  
 
All English women aged 15 to 64 who were registered with CPRD-HES linked practices 
between 1997 and 2011 were included in this study if they had a VTE event. Although this 
data covers only 3% of the wider UK population, the distribution of sex and age in the HES-
CPRD linked data has been reported (Walker et al, 2013) to be comparable to England’s 
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general population. Hence, the study findings may be generalizable to majority of women in 
England. 
 
In addition, CPRD-HES data is recorded in a prospective manner which negates the 
possibility of either recall or selection bias. This also enabled us to use person time in 
computing absolute rates since our study was cohort by design. 
 
This study also had potential limitations. First, we were not able to determine whether 
hormone use was the definite cause of the VTE in those classed as “users” and some of the 
events may have been unprovoked. Similarly, whilst we chose of a window of 6-months to 
class a woman as having had a hormonal related VTE, it is possible that hormone use prior 
to this could still play a role in the event.  However, simply noting whether or not women 
used OCs or HRT in the 6-months preceding a VTE would reflect how these results would be 
utilised in practice. Second, information on other VTE risk factors was limited in the CPRD-
HES database. Therefore, some of the VTE events may have been misclassified as 
unprovoked instead of being provoked by a recognised factor. For example immobility 
related VTE might have been considered as unprovoked since some causes of immobility 
such as long haul travel were not recorded. Thus recurrence rates in non-users could have 
been underestimated and hazard ratios biased towards the null. However, we suspect that 
women with such other risk factors as a percentage of all VTE events would be relatively 
small, in which case the impact on the observed results will not be substantial. Third, 
although VTE recurrence was defined using a standard algorithm, defining VTE recurrence 
may be difficult due to possibility misclassification between index and recurrent events, a 
problem previously recognised in studies using routinely collected healthcare data (Schmidt 
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et al, 2014). However, we accounted for such discrepancy in date by allowing 30 days before 
an event was considered recurrent. Moreover, in sensitivity analysis where an event was 
considered recurrent only if it occurred after 180 days, results remained unaltered but 
rather showed a stronger association. This may be because of either misclassification of first 
VTE as early recurrent VTEs attenuated  the effect size in the first 6 months of follow up or it 
could simply be that the protection is greater long-term if women cease hormonal use after 
their first VTE. Fourth, our effect size could have been further attenuated by the fact we 
observed women with a hormone-related VTE received anticoagulation for a shorter 
duration than those with an unprovoked VTE. However, adjustment for this variable had 
little impact on the hazard ratio in our adjusted model due to anticoagulation duration not 
being associated with recurrence rate in this study. Fifth, we were unable to provide data on 
the bleeding risk in this population. However, as the purpose of this study was to provide 
estimates on absolute and relative risks of recurrent VTE as a whole rather than inform 
individual patient decisions about the appropriate duration of anticoagulation, we do not 
believe this to be a major limitation. Finally, our results will generalise only to women within 
the age range studied. Our age bands were carefully chosen a priori so that our results 
would generalise specifically to young women most likely to be using OCs (15-44 years) and 
women in middle age for which the use of HRT over short periods for relief of menopausal 
symptoms was anticipated to be high (45-64 years).  
  
In this study, we were able to adjust for possible confounding factors like age which is noted 
to play a vital role in VTE recurrence (Heit et al, 2000). As with any study of this type our 
results of this study could be influenced by additional unmeasured factors. In particular, we 
cannot rule out the possibility of the size of our effect reduction being at least in part due to 
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a healthy user effect whereby women who were using hormones at the time of their VTE 
were otherwise healthier than those with unprovoked (Ray, 2003), although it will be very 
difficult to speculate as to the likely magnitude of this effect in the present context.    
 
Comparison with previous studies 
Our finding is inconsistent with data from a trial conducted in Canada and the US (Cushman 
et al, 2006), which reported no significant difference in three year probability of VTE 
recurrence between hormonal users (OCs and HRT) and non-users.  On the other hand, 
results from stratified analysis for women aged 15 to 44 years are consistent with a large US 
based study where users had 42% significantly lower recurrence risk  (Heit et al, 2000), as 
well as a  significantly lower recurrence proportion in an earlier UK study (Badaracco and 
Vessey, 1974).  A probable reason for the observed results in our study may be due to the 
reverse effect in that after cessation of hormone use, the VTE risk is decreased. It is not 
clear whether this phenomenon may be the same for other transient VTE risk factors.   This 
finding however, still disagrees with two other studies (Christiansen et al, 2005;  Le Moigne 
et al, 2013) which found no differences in VTE recurrence rates between OC users and non-
users. Furthermore, findings regarding HRT use are inconsistent with previous studies (Heit 
et al, 2000;  Le Gal et al, 2010).  
One possible explanation for the inconsistent findings may be due to limited statistical 
power to detect differences in measure of effect in previous studies. For example in the 
REVERSE study (Le Gal et al, 2010), only 18 women out of 314 women had used HRT prior to 
the initial VTE event and only 4 women got a VTE recurrence. In such a case, there was high 
possibility of a type II error. In a pooled secondary analyses of seven existing cohorts, the 
authors observed at 50% reduction in recurrence (95% confidence interval 20% to 70%) in 
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women with a hormone associated VTE, supporting the findings of the present study 
(Douketis et al, 2011). However, the total number of women in the cohorts combined 
(n=1286) was less than the number in our cohort, whilst this previous analysis did not 
stratify results according to age and duration of initial anticoagulation in the way in which 
we were able to.  
 
Clinical and policy implications 
Findings from our study imply that in UK, VTE recurrence is an important problem in women 
aged 15 to 64 years.  The reduced risk of VTE recurrence in users compared to non-users 
does not support prolonged anticoagulation and suggests that 3 rather than 6 months of 
anticoagulation treatment may be sufficient for women whose initial VTE is related to 
hormone use in line with current guidelines from the UK and elsewhere.  
Furthermore, our findings highlight that among the sub-group of women treated for less 
than 90 days the absolute risks of VTE were more comparable between hormone users and 
non-users, indicating that anticoagulation for less than 90 days in women with hormone-
related VTE would not be advised.  
 
Using the data we had available, we carried out a secondary analysis to determine 
whether resumption of hormone therapy once anticoagulation therapy had ceased would 
influence the risk of VTE recurrence. Whilst our data found this was not the case, this 
should not be taken to mean that it is safe to resume hormonal therapy in this instance. 
Our study was not originally powered to explore this hypothesis and whilst this secondary 
analysis had slightly more person-years of follow-up and outcome events, only a small 
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number of women (n=797) were in the exposed group. Clinically important real 
differences may therefore have been missed.   
Conclusion 
 
Women whose index VTE is hormone related are at lower risk of VTE recurrence compared 
to those whose index VTE is unprovoked. Therefore prolonged anticoagulation treatment of 
more than 90 days appears to be unjustified. Our study also highlights the need for further 
research both to confirm the findings of the present study and explore whether additional 
factors need to be taken into account when making treatment decisions concerning women 
who develop VTE following exposure to hormones.
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Table I: Characteristics of the study population at index VTE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCs & HRT refers to women who had prescription of both OCs and HRT in the 6 months preceding the first VTE
Characteristic (s)   Users  Non-users   
Age  group 15 to 44 years 45 to 64 years 15 to 44 years 45 to 64 years Total, (%) 
Number, n (%) 603 (14.46) 593 (14.22) 1,116 (26.76) 1,858 (44.56) 4,170(100) 
Age in years, median(IQR) 32(27-39) 55(50-59) 36(30-41) 55(50-60) 48(37-57) 
Type of hormone used, n (%) 
    OCs 562(89.49) 66 (10.51) - - 628 (15.05)   
    HRT 40(7.12) 522(92.88) - - 562 (13.48) 
    OCs & HRT 1(16.67) 5(83.33) - - 6(0.14) 
Time periods, median(IQR) 
Follow up time, years 0.72(0.17-3.01) 1.65(0.24-4.93) 1.96(0.58-4.80) 2.11(0.77-4.34) 1.8 (0.47-4.41) 
Person years of follow up 1,308 1,745 3,461 5,543 1,2056 
Anticoagulation duration, n (%) 
Less than 90 days 234 (49.68) 237(50.32) 453(38.62) 720(61.38) 1,644 (39.42) 
90 or more days 369 (50.90) 356 (49.10) 663(36.81) 1,138(63.19) 2,526 (60.58) 
Calendar year 
1997-1999 46(36.22) 81(63.78) 100(40.98) 144(59.02) 371(8.90) 
2000-2002 115(39.38) 177(60.62) 203(36.25) 357(63.75) 852(20.43) 
2003-2005 126(49.22) 130(50.78) 254(37.52) 423(62.48) 933(22.37) 
2006-2008 161(57.30) 120(42.70) 286(36.48) 498(63.52) 1,065(25.54) 
2009-2011 155(64.58) 85(35.42) 273(38.50) 436(61.50) 949(22.76) 
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Table II: Recurrence rates of VTE stratified by hormonal use, age group and duration of 
anticoagulant therapy 
 
Characteristic(s) Number of 
recurrences/pers
on years 
Absolute 
rates*(95%CI) 
Crude 
HR(95%CI) 
Adjusted 
**HR(95%CI) 
Total VTE 
recurrence  
575/12056 47.7(43.9-51.8) - - 
Hormonal use 
Users 113/3052 37.0(30.8-44.5) 0.73(0.60-0.90) 0.72(0.58-0.88) 
Non-users 462/9004 51.3(46.8-56.2) reference reference 
Age group 
15 to 44 years 248/4768 52(45.9-58.9) reference reference 
45 to 64 years 327/7288 44.8(40.3-50) 0.86(0.73-1.01)  0.86(0.73-1.01) 
Duration of anticoagulation therapy   
Less than 90 days 233/4763 48.9(43.0-55.6) reference reference 
90 or more days 342/7293 46.9(42.1-52.1) 1.18(0.99-1.41) 1.17(0.98-1.40)  
* per 1000 person-years,  ** Adjusted for age, calendar year & anticoagulant duration (when not stratified on 
them), CI- Confidence interval, Age group-≤44 or ≥45 to 64 years at index VTE. Schoenfeld’s test for 
proportional hazards: P=0.3, Log rank test for comparison of survival curves; hormone use P=0.002, age group 
P=0.78, anticoagulant duration P=0.98.  
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Table III: Recurrence rates of VTE in users and non-users of hormones stratified by age and 
duration of anticoagulation 
 
*per 1000 person-years, ** Adjusted for age, calendar year, anticoagulant duration (when not stratified on 
them),  CI- Confidence interval, Schoenfeld’s test for proportional hazards;  ≤44 years P=0.1, >44 years P= 0.9, 
anticoagulant duration P= 0.8. Log rank test for comparison of survival curves; hormone use P=0.04, 
anticoagulant duration P=0.64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic(s) Number of 
recurrences
/person 
years 
Absolute 
rates*(95%CI) 
Crude 
HR(95%CI) 
**Adjusted 
HR(95%CI) 
p-value 
Age 
15 to 44 years 
Total VTE 
recurrence  
248/4768 52(45.9-58.9) - - - 
Users 57/1308 43.6(33.6-56.5) 0.74(0.55-0.99) 0.71(0.52-0.96) 0.02 
Non-users 191/3461 55.2(47.9-63.6) reference reference - 
45 to 64 years 
Total VTE 
recurrence  
     327/7288  44.8(40.3-50.0) - - - 
Users 56/1745 32.1(24.7-41.7) 0.71(0.53-0.94) 0.71(0.53-0.95) 0.02 
Non-users 271/5543 48.9(43.4-55.1) reference reference - 
Duration of anticoagulation therapy 
Less than 90 
days 
233/4763 48.9(43.0-55.6) - - - 
 
Users 47/1109 42.4(31.8-56.4) 0.81(0.59-1.12) 0.77(0.56-1.07) 0.15 
Non-users 186/3653 50.9(44.1-58.8) reference reference - 
 
90 or more days 342/7293 46.9(42.2-52.1) - - - 
 
Users 66/1943 33.9(26.7-43.2) 0.68(0.52-0.89) 0.67(0.51-0.88) 0.004 
Non-users 276/5349 51.6(45.8-58.1) reference reference - 
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Table IV: Recurrence rates of VTE in users and non-users of hormones after 6 months of follow up 
Characteristic(s) Number of 
recurrences
/person 
years 
Absolute 
rates*(95%CI) 
Crude 
HR(95%CI) 
Adjusted 
**HR(95%CI) 
p-value 
Total VTE 
recurrence  
310/1200 25.8(23.1-28.9) - - - 
15 to 64 years 
Users 47/3041  15.5(11.6-20.6) 0.54(0.40-0.74) 0.54(0.39-0.74) <0.001 
Non-users 263/8968  29.3(25.9-33.1) reference reference - 
15 to 44 years 
Users 20/1301  15.4(9.9-23.8) 0.48(0.30-0.79) 0.46(0.28-0.75) 0.004 
Non-users 107/3445 31.1 (25.7-37.5) reference reference - 
45 to 64 years 
Users 27/1740  15.5(10.6-22.6) 0.58(0.39-0.88) 0.59(0.39-0.89) 0.011 
Non-users 156/5522  28.3(24.1-33.1) reference reference - 
* per 1000 person-years, HR-Hazard ratio, CI-confidence interval, **Adjusted for age, anticoagulant duration & 
calendar year (when not stratified on them), Schoenfeld’s test for proportional hazards P= 0.6 
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Table V Recurrence rates of VTE following resumption of hormone use (15 to 64 years) 
 
 
Characteristic(s) Number of 
recurrences
/person 
years 
Absolute 
rates*(95%CI) 
Crude 
HR(95%CI) 
Adjusted 
**HR(95%CI) 
p-value 
All women (n=4,170) 
Follow-up Users  66/2601  25.4(19.9-32.3) 0.95(0.72-1.25) 0.97(0.73-1.27) 0.80 
Follow-up non-
users 
572/12063  47.4(43.7-51.4) reference reference - 
 
Hormones non-users at baseline (n=2,973) 
Hormone 
initiators 
23/967  23.8(15.8-35.8) 0.90(0.58-1.38) 0.89(0.58-1.38) 0.61 
Non-initiators 460/9011 51.1 (46.6-55.9) reference reference - 
 
Hormone users at baseline (n=1,196) 
Hormone 
resumption 
43/1633  26.3(19.5-35.5) 1.06(0.74-1.53) 1.13(0.78-1.63) 0.52 
Non-resumption 112/3052  36.7(30.5-44.2) reference reference - 
* per 1000 person-years, , **Adjusted for age, anticoagulant duration & calendar year. The analysis of all 
women also adjusts for whether they were hormone-users at baseline. P-values were obtained from the 
adjusted models.  
HR-Hazard ratio, CI-confidence interval 
Hormone resumption/imitation was fitted as a time-varying covariate in all models 
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Figure 1: Nelson-Aalen cumulative hazard estimates of the probability of VTE recurrence 
in hormone users and non-users 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
